07.18.19

Clearside Biomedical Announces Multiple Oral Presentations to be Given at the ASRS Annual Meeting

Source: Clearside Biomedical

Clearside Biomedical announced that multiple oral presentations on Clearside’s pipeline and proprietary SCS Microinjector targeting the suprachoroidal space will be given at the upcoming American Society of Retinal Specialists (ASRS) annual meeting taking place July 26-30, 2019 in Chicago. 

In addition, Thomas A. Ciulla, MD, MBA, Chief Medical Officer of Clearside, will speak on a panel entitled, “Advancements in Genetic and Regenerative Therapies”, at the Ophthalmology Innovation Summit event (OIS at ASRS) on Thursday, July 25, 2019 from 1:35-2:15 pm Central Time.  The agenda for OIS at ASRS can be found here:https://ois.net/ois-asrs-2019/agenda/.

Christine N. Kay, M.D., Vitreo Retinal Associates; Affiliate Assistant Professor in the Department of Ophthalmology, University of South Florida
Title:                Suprachoroidally delivered gene therapy via non-viral DNA nanoparticles
Date:               Video presentation available as a Paper-on-Demand

Michael S. Ip, M.D., Doheny Eye Institute, David Geffen School of Medicine at University of California Los Angeles, CA
Symposium:    Diabetic Retinopathy Part I
Title:               Suprachoroidal CLS-TA Plus Aflibercept Compared With Aflibercept Monotherapy for Diabetic Macular Edema (DME): Results of a Phase 2 Trial
Date:               Monday, July 29, 2019
Time:              11:10 am

Christopher R. Henry, M.D., Retina Consultants of Houston
Symposium:    Inflammatory and Infectious Diseases
Title:               Suprachoroidal CLS-TA Improves Patient Outcomes in Uveitis of All Anatomic Subtypes: Results of the Phase 3 PEACHTREE Study
Date:               Tuesday, July 30, 2019
Time:              10:26 am

Pauline T. Merrill, M.D., Illinois Retina Associates; Assistant Professor in the Department of Ophthalmology, Rush University Medical Center
Symposium:    Inflammatory and Infectious Diseases
Title:               Suprachoroidally Injected CLS-TA in Uveitis Maintains Efficacy Outcomes Through 48 Weeks: Results of the MAGNOLIA Phase 3 Extension Study
Date:               Tuesday, July 30, 2019
Time:              10:30 am

Milan Shah, M.D., Midwest Eye Institute
Symposium:    Instrumentation and Devices
Title:               Clinical Experience With the SCS Microinjector™ for Suprachoroidal Injections by Ophthalmologists
Date:               Tuesday, July 30, 2019
Time:              12:12 pm

 

Related Content